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ABSTRACT Highly accurate testing for severe acute respiratory syndrome coronavi-
rus 2 (SARS-CoV-2) at the point of care (POC) is an unmet diagnostic need in emer-
gency care and time-sensitive outpatient care settings. Reverse transcription-PCR
(RT-PCR) technology is the gold standard for SARS-CoV-2 diagnostics. We performed
a multisite U.S. study comparing the clinical performance of the first U.S. Food and
Drug Administration (FDA)-authorized POC RT-PCR for detection of SARS-CoV-2 in 20
min, the cobas Liat SARS-CoV-2 and influenza A/B nucleic acid test, to the most widely
used RT-PCR laboratory test, the cobas 68/8800 SARS-CoV-2 test. Clinical nasopharyn-
geal swab specimens from 444 patients with 357 evaluable specimens at five U.S. clini-
cal laboratories were enrolled from 21 September 2020 to 23 October 2020. The over-
all agreement between the Liat and 68/8800 systems for SARS-CoV-2 diagnostics was
98.6% (352/357). Using Liat, positive percent agreement for SARS-CoV-2 was 100%
(162/162) and the negative percent agreement was 97.4% (190/195). The Liat is an RT-
PCR POC test that provides highly accurate SARS-CoV-2 results in 20 min with per-
formance equivalent to that of high-throughput laboratory molecular testing. Rapid
RT-PCR testing at the POC can enable more timely infection control and individual
care decisions for coronavirus disease 2019.
KEYWORDS coronavirus disease 2019 (COVID-19), cobas 68/8800 SARS-CoV-2, cobas
Liat SARS-CoV-2 and influenza A/B, Liat, point-of-care (POC), reverse transcription-
polymerase chain reaction (RT-PCR)
Anovel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),the agent of coronavirus disease 2019 (COVID-19), has led to a global pandemic
with widespread morbidity and mortality since first emerging in China in December
2019 (1). With limited curative therapeutics and no widely available preventative vacci-
nation, timely and accurate diagnostic testing is vital to contain the spread of infection
and reduce harmful delays in care delivery (2). However, widespread testing shortages
due to the enormous global demand have hampered current diagnostic efforts (3),
and longer turnaround times (TAT) of available highly accurate diagnostics can limit
their clinical applications.
Consistent with recommendations from the Infectious Diseases Society of America
(IDSA) (4), the majority of SARS-CoV-2 testing being performed in the United States is
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with nucleic acid amplification tests (NAATs), the majority of which are performed on
high-throughput automated laboratory testing systems. IDSA also underscores the im-
portance of result timeliness; however, laboratory-based platforms routinely take sev-
eral hours to days to provide results and are therefore not compatible with rapid isola-
tion of infected patients, appropriate deployment of personal protective equipment
(PPE), and initiation of treatment workflows required for emergency care and time-sen-
sitive outpatient settings.
Currently, point-of-care (POC) diagnostics for SARS-CoV-2 with TAT that are rapid
(defined here as TAT of less than 30 min for all results [5]) utilize technologies (such as
isothermal NAAT or lateral flow antigen testing) which are less clinically sensitive than
widely used but primarily laboratory-based reverse transcription-PCRs (RT-PCRs) (6, 7).
The widespread availability of sensitive and specific POC testing for SARS-CoV-2 remains
an unmet diagnostic and clinical need.
In September 2020, the U.S. Food and Drug Administration (FDA) authorized the
first rapid POC test for SARS-CoV-2 that utilizes RT-PCR technology (8). The cobas
SARS-CoV-2 and influenza A/B nucleic acid test for use on the cobas Liat system (here
referred to as Liat) (Roche Molecular Systems, Inc., Pleasanton, CA) received emergency
use authorization (EUA) for the identification and differentiation of SARS-CoV-2, influ-
enza A virus, and influenza B virus using RT-PCR in POC settings in 20 min. This multi-
site U.S. study is the first to evaluate the real-world performance of the Liat test for
detection of SARS-CoV-2.
MATERIALS ANDMETHODS
The objective of this study was to evaluate the clinical performance of the Liat for the detection of
SARS-CoV-2 in nasopharyngeal swab specimens using the cobas SARS-CoV-2 nucleic acid test on the
cobas 6800 and 8800 systems (here referred to as 68/8800) as the reference method.
Liat SARS-CoV-2 and influenza A/B test. The Liat system is for in vitro diagnostic (IVD) use and pro-
vides Clinical Laboratory Improvement Amendments-waived random access POC molecular testing in a
compact countertop system. The system is designed to identify and measure the presence of genetic
material in a biological specimen. The system automates NAAT processes, including target enrichment,
inhibitor removal, nucleic acid extraction, amplification, real-time detection, and result interpretation in
a rapid manner, from specimen to result in 20 min.
The Liat SARS-CoV-2 and influenza A/B test is a multiplex RT-PCR for the rapid in vitro detection and
discrimination of RNA targets for three viruses—SARS-CoV-2, influenza A virus, and influenza B virus—in
nasal or nasopharyngeal swabs preserved in transport media. In the United States, the test has been
authorized for use in both laboratory and nonlaboratory POC settings (9). Test performance for influenza
A/B virus detection as well as overall assay workflow and field usability were established in previous
studies (10–12) of the cobas influenza A/B and respiratory syncytial virus (RSV) test (deployed in 2017
worldwide), upon which the Liat SARS-CoV-2 and influenza A/B test was built by removing RSV detection
and adding SARS-CoV-2 detection. Consistent with the prospectively evaluated performance of the
cobas influenza A/B and RSV test, detection of influenza A/influenza B for the cobas influenza A/B
and SARS-CoV-2 test is similarly expected to yield respective values for positive percent agreement
(PPAs) of 98.8 to 100% and 97.8 to 100% and values for negative percent agreement (NPAs) of 97.1
to 98.8% and 96.3 to 99.7% for influenza A and B viruses compared with other FDA-cleared and labo-
ratory-based RT-PCRs (10, 11, 13, 14).
For SARS-CoV-2 detection, the test utilizes a dual-target design such that a positive result is gener-
ated if either or both of two target regions (ORF1a/b and N gene) of the SARS-CoV-2 genome are
detected. An internal process control is added to all specimens. Limit-of-detection (LoD) studies using
heat-inactivated cultured virus (USA-WA1/2020 strain, lot 324047, stock concentration of 3.16 106 50%
tissue culture infective doses [TCID50]/ml; Zeptometrix, NY) demonstrated that detection rates were 95%
or higher at a concentration of 0.012 TCID50/ml for SARS-CoV-2 (15).
68/8800 SARS-CoV-2 test. The 68/8800 SARS-CoV-2 test is an analytically sensitive and accurate
test with demonstrated clinical performance (16, 17); it is the most widely used platform for SARS-CoV-2
diagnostics in the United States (8, 18). The 68/8800 platform offers high-throughput testing and is auto-
mated for nucleic acid extraction and RT-PCR. Detection with 68/8800 SARS-CoV-2 utilizes a dual-target
design (ORF1a/b and E gene) reported through two separate channels. Detection of either or both tar-
gets is considered a positive SARS-CoV-2 clinical result. LoD studies using heat-inactivated cultured virus
(USA-WA1/2020, lot 70033175, stock concentration of 2.8 105 TCID50/ml; Zeptometrix, Buffalo, NY)
demonstrated that detection rates were 95% or higher for concentrations of 0.009 TCID50/ml and 0.003
TCID50/ml for target 1 (ORF1a/b) and target 2 (E gene), respectively (18). The Liat and 68/8800 tests detect dif-
ferent regions of ORF1a/b.
Specimen collection and testing. Five clinical laboratories across the United States (Davis, CA;
Chicago, IL; Minneapolis, MN; New York, NY; and Philadelphia, PA) provided prospective specimens
for the study. Specimens were indicated for testing based on the institutional criteria, which
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included the testing of both symptomatic and asymptomatic patients. Fresh and deidentified clinical
nasopharyngeal swab specimens were collected into 3-ml Becton, Dickinson and Company (Franklin
Lakes, NJ)/Copan (Murrieta, CA) universal transport medium (UTM) or Remel (San Diego, CA) viral
transport medium (VTM) at clinical sites and tested with 68/8800 and Liat according to the EUA man-
ufacturer instructions. While the 68/8800 test is not indicated for use with VTM according to the EUA
manufacturer instructions, three clinical laboratories (CA, IL, and MN) validated VTM for routine clini-
cal use and utilized it in the study in accordance with the study protocol. Results for SARS-CoV-2
were determined using the 68/8800 according to established testing procedures at each respective
clinical laboratory; however, Liat test operators were blinded to any prior specimen test results. Each
site targeted enrollment of 40 positive and 40 negative specimens, testing a mix of negative and
positive specimens on each day of testing throughout enrollment. Testing was performed on both
systems within 72 h of specimen collection and all specimens were stored at 2 to 8°C if testing was
not performed within 4 h of specimen collection. The same specimen was used for testing on both
systems.
Collected specimens were excluded for Liat testing if (i) specimen storage was not compliant with
stability requirements, (ii) 500ml of specimen was not available for Liat testing after completing testing
with 68/8800, (iii) specimens were collected outside the nasopharynx, and (iv) specimens were not col-
lected in designated media.
Liat testing was initiated on 21 September 2020 and completed on 23 October 2020. Specimen col-
lection and testing procedures were approved by each site’s institutional review board (IRB) and were
conducted in compliance with the protocol, applicable International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, and good clinical practice
(GCP) guidelines. Study-specific informed consent was not necessary due to the use of remnant, deiden-
tified specimens.
Statistical analysis. The overall percent agreement (OPA), PPA, and NPA for Liat results were cal-
culated with corresponding Wilson 95% confidence intervals (CIs) compared with the positive and
negative results on 68/8800. Consistent with FDA guidance, sensitivity and specificity were not used
to describe the results since there is no established reference method for SARS-CoV-2 at this time.
Valid and invalid test results were determined and summarized. Analyses of cycle threshold (CT) val-
ues were performed on valid test results. Reports of protocol deviations and incidents from clinical
sites were evaluated descriptively. All data analyses were performed using SAS/STAT software (ver-
sion 9.4; SAS, Cary, NC). Based on a priori power and statistical calculations, collection of at least 120
positives (as determined by 68/8800) was targeted in order to achieve PPA/NPA of approximately
98% and a 95% lower CI bound of approximately 95%. CT values were recorded for both tests to sup-
port investigation of discordant results.
RESULTS
Specimen disposition. A total of 444 nasopharyngeal swab specimens were col-
lected from five study sites. Eighty-four specimens (32 positives and 52 negative) did
not meet the inclusion criteria and were ineligible: 51 due to the utilization of off-pro-
tocol collection media, 28 due to testing outside the stability window, and 5 due to
pooled 68/8800 testing. Three specimens were nonevaluable since they were invalid
upon initial and repeat Liat testing. There were 357 evaluable specimens (162 SARS-
CoV-2-positive and 195 SARS-CoV-2-negative specimens) based on the result from the
68/8800 test included in the final analysis. Enrollment and representation of positive
specimens were not equally distributed across study sites due to differences in COVID-
19 prevalence and availability of specimens collected in eligible collection media. As a
result, two sites (CA and MN) were asked to extend enrollment beyond 40 positive and
40 negative specimens, because they were not impacted by these limitations.
Specimen disposition is shown in Table 1.
Test performance. Table 2 compares the performance between the Liat and 68/
8800 tests. The Liat test demonstrated 100% PPA (95% CI, 97.7 to 100%), 97.4% NPA
(95% CI, 94.1 to 98.9%) and 98.6% OPA (95% CI, 96.8 to 99.4%) with the 68/8800. In
total, 354 specimens yielded initial valid results on the Liat and 6 specimens yielded an
initial invalid result (initial invalid rate, 1.66% [6/360]), out of which 3 yielded valid
results when repeated per the instructions for use; this resulted in the 357 evaluable
specimens.
Discordant specimens. Five specimens were discordant, with Liat-positive and 68/
8800-negative results: four specimens were collected in UTM that is indicated for use
by both tests and one specimen was collected in VTM; this was on protocol but is indi-
cated for use with the Liat only. Figure 1 shows the CT values for all Liat-positive results.
Discordant specimens all had relatively delayed CT values (indicative of a lower viral
Liat SARS-CoV-2 Test Journal of Clinical Microbiology
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concentration in the specimen) of 32.2, 32.6, 33.5, 33.6, and 37.4. Concordant speci-
mens had CT values ranging from 10.1 to 35.0, with median of 19.5.
DISCUSSION
The Liat test demonstrated excellent test agreement (98.6% OPA, 100% PPA, and
97.4% NPA) with a widely used laboratory RT-PCR for SARS-CoV-2 detection in a
multisite U.S. study. With a 20-min TAT and EUA approval for POC use, this study
demonstrates that the Liat test enables rapid and accurate POC detection of SARS-
CoV-2.
Discordance between comparably performing molecular tests—in this case the Liat
and 68/8800 tests—is commonly observed for SARS-CoV-2 and other microorganisms
when very low concentrations of viral RNA are present in the specimen (16, 17). In this
study, all five discordant specimens had visually delayed CT values (Fig. 1) compared to
the concordant specimens, indicative of lower viral concentrations. Moreover, these
discordant specimens had CT values near the LoD previously reported for the Liat test
(19). LoD evaluations suggest that comparable and very low viral concentrations can
be detected by both assays; however, the translation of analytical to clinical sensitivity
can be impacted by many variables, such as testing conditions and normal run-to-run
variation. Ultimately, the clinical significance (such as transmissibility and infectious-
ness) for patients with specimens containing low concentrations of SARS-CoV-2 is not
fully understood and is under active investigation (20).
Several current POC tests using non-RT-PCR technologies for SARS-CoV-2 can be
rapidly performed, i.e., in less than 30 min; however, poorer analytical sensitivities (rela-
tive to RT-PCR) of these tests translate to increased clinical false negativity (21–23). For
example, following EUA availability of the POC Abbott ID NOW COVID-19 test, wide-
spread adverse-event reporting of inaccurate negative results led to a recommenda-
tion from the FDA to confirm all negative SARS-CoV-2 results with a sensitive molecular
test (24). This finding for SARS-CoV-2 testing is consistent with the performance of sim-
ilar non-RT-PCR POC tests for influenza, where rapid diagnostic tests, diffusion immu-
TABLE 2 Comparison of Liat with 68/8800 for the detection of SARS-CoV-2
cobas Liat SARS-CoV-2 result
No. of samples with indicated
cobas 68/8800 SARS-CoV-2 result
TotalPositive Negative
Detected 162 5 167
Not detected 0 190 190
Total 162 195 357
TABLE 1 Specimen disposition of the 444 nasopharyngeal swab specimens collected and tested in the studya
Site












windown + 2 n
Invalid Liat
result
CA 105 52 53 0 0 1 0 0 1 106
IL 34 16 18 1 1 27 0 0 27 62
MN 116 58 58 1 1 0 0 0 0 117
NY 34 18 16 1 1 56 51 5 0 91
PA 68 18 50 0 0 0 0 0 0 68
Total 357 162 195 3 3 84 51 5 28 444
aAbbreviations: CA, University of California, Davis, CA; IL, The University of Chicago Medicine, Chicago, IL; MN, Hennepin County Medical Center, Minneapolis, MN; NY, New
York-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY; PA, Jefferson Hospital, Philadelphia, PA.1, positive;2, negative.
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noassays, and isothermal POC NAATs have documented lower performance than RT-
PCR (25).
The unmet and enormous global demand for SARS-CoV-2 tests has also resulted
in significant public discourse regarding the benefits of highly accurate and clini-
cally sensitive NAATs given the existing constraints (availability and ease of use)
compared with lower-clinical-sensitivity technologies, like rapid antigen tests, that
are easier to deploy at high volumes (26, 27). In outpatient settings where the alter-
native choices are either “no test” or an accurate laboratory-based molecular test
(with a long TAT), the benefits of less sensitive rapid antigen technologies should
be considered. However, in other contexts, such as where critical infection control
decisions rely on accurate test results, rapid assays with lower clinical sensitivity are
not acceptable. Future research is required to validate these various testing modal-
ities and define strategies that optimize clinical performance and reagent supply as
the pandemic evolves.
In contrast to rapid tests using non-RT-PCR technologies, the Liat test provides
speed and highly accurate and clinically sensitive performance (21). To date, the only
other RT-PCRs for SARS-CoV-2 close to this profile are the Xpert Xpress SARS-CoV-2
(28) and Xpert Xpress SARS-CoV-2/Flu/RSV assays (29) when used at the POC on the
Xpert Xpress system, with TAT of 45 min (30-min early callout for positives) and 36
min (25-min early callout for positives), respectively. Rapid highly accurate specimen-
to-answer platforms are not scalable to replace high-throughput automated labora-
tory systems. Instead, they should be deployed to complement these platforms. The
Liat can add significant value in settings where immediate accurate results for indi-
vidual patients can improve care and reduce the use of valuable resources. Examples
include emergency settings, time-sensitive procedures such as surgery, and targeted
outpatient settings.
In emergency settings, it is crucial to know whether an individual patient is
positive for the virus. During peak periods of the pandemic, effective use of
resources is critical, both to improve morbidity and mortality of SARS-CoV-2
patients and to prevent the further spread of the virus. Identifying SARS-CoV-2-
positive patients at the point of admission facilitates this by enabling effective
patient cohorting and discharge to congregate living facilities, providing
FIG 1 CT values for all evaluable Liat-positive results by site. All 167 evaluable specimens with
positive Liat results were included, including the 5 discordant specimens.
Liat SARS-CoV-2 Test Journal of Clinical Microbiology
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information about the level of infection control required, targeting resources such
as PPE appropriately, and accelerating enrollment into drug trials and/or adminis-
tration of EUA therapies.
For time-sensitive procedures and high-risk surgeries, especially continuous-aero-
sol-generating procedures (such as in orthopedics [30] and otorhinolaryngology [31]),
many hospitals are using a COVID-19 testing protocol which can be instituted up to
96 h in advance of hospital admission to confirm that patients are negative (32).
Preprocedure testing often relies on high-throughput laboratory-based platforms and
has limited use for urgent or unexpected problems encountered in trauma, emergency
medicine, deceased-donor transplant (33), and obstetrics. For these special cases, rapid
confirmation of negative SARS-CoV-2 status saves time and resources by preventing
unnecessary use of contact precautions.
Outpatient settings may require confirmation of negative SARS-CoV-2 status for
the patient to receive care. The Liat SARS-CoV-2 influenza A/B test provides accu-
rate rapid-response testing for symptomatic individuals with preexisting risk factors
for COVID-19 mortality/morbidity. The fast TAT (20 min) of the Liat could also be
leveraged by health care facilities for symptomatic frontline employees and COVID-
19 cluster investigation to quickly rule out negative individuals and facilitate their
return to work.
The Liat SARS-CoV-2 and influenza A/B test that was utilized in this evaluation has
the additional benefit of testing for influenza at the same time as SARS-CoV-2; this pro-
vides further important information for symptomatic patients by allowing differential
diagnosis when multiple respiratory viruses are in circulation (34). POC RT-PCR testing
for influenza in the clinic can be used to guide patient care decisions (35) and has
been shown to be effective at reducing inappropriate prescribing of antibiotics (36) as
well as potentially reducing the length of stay in hospital (37). In addition, the Liat has
demonstrated cost savings to hospital systems when deployed in the emergency
department for respiratory pathogen testing (34, 35).
This study has several limitations. First, clinical patient-level data (such as the
duration of symptoms) were not collected and analysis was limited to test perform-
ance comparisons; this limited further investigation into the clinical significance of
specimens with very low concentrations of virus. Second, because the enrollment
period occurred prior to the start of the winter respiratory season, we were not able
to assess the clinical performance for influenza A and B detection in this study.
Third, an equal proportion of negative specimens was included in the study in order to
preserve scarce testing supplies for clinical use, so prevalence does not reflect a real-world
population. Lastly, further testing of the specimens to investigate discordant results was
not possible.
In conclusion, the Liat is the first RT-PCR assay capable of reporting results in 20
min at the point of care. The evaluation demonstrates equivalent performance to high-
throughput laboratory RT-PCR testing and fills an unmet diagnostic need in frontline
settings to accurately and rapidly test for SARS-CoV-2. This favors use in settings where
immediate decision making is required for treatment, PPE, and infection prevention
decisions.
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